NO20083288L - Konjungat for behandling av tumorer - Google Patents

Konjungat for behandling av tumorer

Info

Publication number
NO20083288L
NO20083288L NO20083288A NO20083288A NO20083288L NO 20083288 L NO20083288 L NO 20083288L NO 20083288 A NO20083288 A NO 20083288A NO 20083288 A NO20083288 A NO 20083288A NO 20083288 L NO20083288 L NO 20083288L
Authority
NO
Norway
Prior art keywords
tumors
treatment
antitumor
conjugate
specific
Prior art date
Application number
NO20083288A
Other languages
English (en)
Inventor
Yongzhang Luo
Qingxin Lei
Guodong Chang
Hao Zhou
Original Assignee
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protgen Ltd filed Critical Protgen Ltd
Publication of NO20083288L publication Critical patent/NO20083288L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)

Abstract

Det beskrives et antitumorprotein koblet med en spesifikt modifiserende reagens ved et spesifikt sete for å overkomme iboende mangler til antitumorproteinet, så som høy antigenisitet og kort halveringstid, og for å omgå manglene som er resultatet av ikke-spesifikt modifiserende metoder, så som inkonsistente modifiserte seter, inhomogene bestanddeler, signifikant redusert aktivitet og kvalitet som er vans.kelig åregulere i produktene, og for til slutt å gjøre det mulig ved behandling av tumorer og produksjon av antitumormedikamenter.
NO20083288A 2006-01-20 2008-07-24 Konjungat for behandling av tumorer NO20083288L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200610011246A CN101002945B (zh) 2006-01-20 2006-01-20 一种用于肿瘤治疗的新型复合物
PCT/CN2007/000203 WO2007082482A1 (fr) 2006-01-20 2007-01-19 Nouveau composé de traitement de tumeur

Publications (1)

Publication Number Publication Date
NO20083288L true NO20083288L (no) 2008-10-20

Family

ID=38287272

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083288A NO20083288L (no) 2006-01-20 2008-07-24 Konjungat for behandling av tumorer

Country Status (8)

Country Link
US (1) US20100303893A1 (no)
EP (1) EP1987838B1 (no)
JP (1) JP2009523433A (no)
CN (1) CN101002945B (no)
AU (1) AU2007207267B2 (no)
CA (1) CA2637687C (no)
NO (1) NO20083288L (no)
WO (1) WO2007082482A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010144A1 (en) * 2009-04-03 2012-01-12 Ragheb Assaly Peg-albumin composition having at least one protected thiol region as a platform for medications
AU2012267200B2 (en) * 2011-06-06 2016-02-25 Starpharma Pty Ltd Macromolecules
TW201735943A (zh) 2012-04-04 2017-10-16 普拉瑞斯集團 利用精胺酸去亞胺酶之治療方法
US9506897B2 (en) * 2012-11-16 2016-11-29 Agilent Technologies, Inc. Methods and compositions for improved ion-exchange chromatography
USRE48805E1 (en) 2013-03-06 2021-11-02 Vision Global Holdings Ltd. Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
US9255262B2 (en) 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
WO2014151982A2 (en) 2013-03-15 2014-09-25 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
WO2015143006A1 (en) 2014-03-18 2015-09-24 Tdw Group Engineered chimeric pegylated adi and methods of use
CN104031261B (zh) * 2014-06-20 2017-10-27 电子科技大学 温敏性共聚物及其水凝胶体系
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CN114522225A (zh) 2014-09-16 2022-05-24 瑞华药业集团 用于癌症治疗的对adi-peg20抗体具有降低的交叉反应性的精氨酸脱亚氨酶
CN105801870B (zh) * 2016-04-08 2018-08-21 北京华熙海御科技有限公司 一种聚唾液酸-透明质酸复合凝胶的制备方法及所得产品和应用
CN108265068B (zh) * 2016-12-31 2021-06-15 江苏众红生物工程创药研究院有限公司 重组精氨酸脱亚胺酶及其产业化制备方法和应用
CN110870869A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 包含糖类营养素和常规无效化合物的药物组合物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911929A (en) 1986-08-29 1990-03-27 The United States Of America As Represented By The Secretary Of The Navy Blood substitute comprising liposome-encapsulated hemoglobin
AU5858690A (en) * 1989-06-14 1991-01-08 Cetus Corporation Polymer/antibiotic conjugate
JP2900279B2 (ja) 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
JP3209338B2 (ja) * 1990-09-10 2001-09-17 株式会社ジャパンエナジー ポリエチレングリコール修飾アルギニンデイミナーゼおよびその製造法
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US6635462B1 (en) * 1997-05-12 2003-10-21 Phoenix Pharmacologies, Inc. Mutated form of arginine deiminase
DE69909747T2 (de) 1998-02-09 2004-04-15 Enzon Pharmaceuticals, Inc. Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen
US6689762B1 (en) 1998-02-09 2004-02-10 Enzon Pharmaceuticals, Inc. Composition and methods for treatment of HIV infection
EP2110381A1 (en) 1999-05-17 2009-10-21 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
AU781380B2 (en) 1999-09-07 2005-05-19 Conjuchem Biotechnologies Inc. Pulmonary delivery for bioconjugation
EP1337630A2 (en) 2000-11-28 2003-08-27 Phoenix Pharmacologics, Inc. Modified arginine deiminase
HK1053577A2 (en) * 2002-06-20 2003-10-10 Bio Cancer Treatment Int Ltd Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation
WO2004000148A2 (en) * 2002-06-25 2003-12-31 Glucon Inc. Method and apparatus for performing myocardial revascularization
AU2003282883B2 (en) * 2002-11-18 2008-12-04 Polaris Group Methods for inhibiting viral replication in vivo
JP2006519235A (ja) 2003-02-26 2006-08-24 インターミューン インコーポレイティッド ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
CN1536079A (zh) * 2003-04-09 2004-10-13 上海复旦张江生物医药股份有限公司 修饰的精氨酸脱亚氨酶
DE602004028725D1 (de) * 2003-05-12 2010-09-30 Affymax Inc Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
ES2387028T3 (es) 2003-12-31 2012-09-12 Merck Patent Gmbh Proteína de fusión de Fc-eritropoyetina con farmacocinética mejorada
CN100355784C (zh) 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α－干扰素1b的制备方法
JP2005245269A (ja) 2004-03-03 2005-09-15 Nipro Corp 血清アルブミン多量体を含む遺伝子組換え型蛋白質
WO2005111072A2 (en) 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
CN1311867C (zh) 2004-09-27 2007-04-25 侯新朴 一种用于鼻腔给药的神经生长因子制剂

Also Published As

Publication number Publication date
JP2009523433A (ja) 2009-06-25
EP1987838A4 (en) 2010-02-24
CA2637687C (en) 2015-07-14
EP1987838B1 (en) 2016-01-13
WO2007082482B1 (fr) 2007-09-07
CA2637687A1 (en) 2007-07-26
CN101002945A (zh) 2007-07-25
EP1987838A1 (en) 2008-11-05
CN101002945B (zh) 2012-09-05
AU2007207267A1 (en) 2007-07-26
US20100303893A1 (en) 2010-12-02
WO2007082482A1 (fr) 2007-07-26
AU2007207267B2 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
NO20083288L (no) Konjungat for behandling av tumorer
MX2019001726A (es) Molecula de union a antigeno capaz de unir repetidamente a la pluralidad de moleculas de antigeno.
MX2018008680A (es) Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).
WO2009126934A3 (en) Detection and tratment of pancreatic, ovarian and other cancers
WO2010002862A3 (en) Fibroblast growth factor receptor 3 (fgfr3) binding proteins
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
SG170091A1 (en) Anti-5t4 antibodies and uses thereof
UA95958C2 (en) Antibody that binds to cd22, immunoconjugates and uses therefor
WO2008027837A3 (en) Small molecule potentiator of hormonal therapy for breast cancer
SG155931A1 (en) Wnt proteins and detection and treatment of cancer
AU2007221366A8 (en) Oxyntomodulin derivatives
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
TW200744568A (en) Epinephrine dosing regimens
NO20082683L (no) Neuroendokrin tumorbehandling
TW200720187A (en) Improvements in thin film production
WO2007062174A3 (en) Devices and methods for high-pressure refolding of proteins
WO2007067984A3 (en) Neutralizing antibodies against primate psgl-1 and uses therefor
Dantuluri et al. Proteome targets of ubiquitin‐like samp1ylation are associated with sulfur metabolism and oxidative stress in Haloferax volcanii
WO2006110496A3 (en) Activation of sodium potassium atpase
Wang et al. How the conformational movement of the substrate drives the regioselective C–N bond formation in P450 TleB: insights from molecular dynamics simulations and quantum mechanical/molecular mechanical calculations
Yang et al. Dissolution of antibiotics mycelium in ionic liquids: Performance and mechanism
WO2009100327A3 (en) Methods of diagnosing chronic prostatitis/chronic pelvic pain syndrome
WO2008118324A3 (en) Composition and method of treating cancer with an anti-uroplakin ib antibody
WO2007134274A3 (en) Antibodies to urokinase- type plasminogen activator receptor(upar)bind cancer stem cells: use in diagnosis and therapy
WO2005114216A3 (en) Stamp2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application